TBPH - Theravance Biopharma, Inc.
| Previous Close | 16.88 |
| Open | 16.85 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 900 |
| Day's Range | 16.81 - 17.35 |
| 52 Week Range | 15.18 - 30.34 |
| Volume | 290,035 |
| Avg. Volume | 240,730 |
| Market Cap | 962.829M |
| Beta (3Y Monthly) | 1.47 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.05 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 36.00 |
- Zacks
Theravance Pipeline Strong, Dependence on Yupelri a Concern
Theravance's (TBPH) newly-launched COPD drug Yupelri is witnessing a solid adoption while its pipeline programs are also progressing well. However, excessive reliance on Yupelri for revenues is a woe.
- Simply Wall St.
Have Insiders Been Selling Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
- Zacks
AstraZeneca's Triple-Combo COPD Inhaler Gets CRL From FDA
AstraZeneca (AZN) gets CRL from the FDA for PT010, its triple-combo inhaler to treat COPD.
- PR Newswire
Theravance Biopharma to Present at the 2019 Cantor Global Healthcare Conference
DUBLIN , Sept. 25, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that management will participate in a fireside chat at the 2019 Cantor Global Healthcare Conference on ...
- GuruFocus.com
Seth Klarman Further Increases Translate Bio Stake
Baupost leader ups bet on biotech company that focuses on genetic diseases Continue reading...
- GuruFocus.com
Baupost's Seth Klarman Dives Further Into Translate Bio
Guru adds to position in biotech company that focuses on genetic diseases Continue reading...
- Zacks
Theravance Announces Positive Early Data on JAK Inhibitor
Theravance's (TBPH) investigational JAK inhibitor TD-8236 demonstrates favorable results from a phase I study for treating inflammatory lung diseases.
- PR Newswire
Theravance Biopharma Reports Positive Results from Phase 1 Clinical Trial of TD-8236, an Investigational, Lung-Selective, Inhaled Pan-Janus Kinase (JAK) Inhibitor for Inflammatory Lung Diseases
DUBLIN, Sept. 9, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced initial results, including positive biomarker responses, from its Phase 1 single-ascending dose (SAD) and multiple-ascending dose (MAD) clinical trial of TD-8236, an investigational, lung-selective inhaled pan-Janus kinase (JAK) inhibitor for inflammatory lung diseases. TD-8236 is specifically designed to be delivered to the lung via dry powder inhalation, targeting airway inflammation in the lung with minimal systemic exposure.
- PR Newswire
Theravance Biopharma to Present at Two Upcoming Investor Conferences
DUBLIN , Aug. 28, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that members of management will participate in fireside chats at two upcoming investor conferences: 14 th ...
- Zacks
Spectrum Pharma's (SPPI) Loss Narrows in Q2, Stock Rises
Spectrum Pharma (SPPI) beats bottom-line estimates in the second quarter.
- Simply Wall St.
How Theravance Biopharma, Inc. (NASDAQ:TBPH) Can Impact Your Portfolio Volatility
Anyone researching Theravance Biopharma, Inc. (NASDAQ:TBPH) might want to consider the historical volatility of the...
- Zacks
Achillion (ACHN) Reports Wider Y/Y Loss in Q2, Revenues Nil
Achillion (ACHN) meets bottom-line estimates in the second quarter. The absence of an approved product results in no revenues in the quarter.
- Zacks
Esperion (ESPR) Q2 Loss Wider Than Expected, Revenues Beat
Esperion Therapeutics (ESPR) reports mixed second-quarter results.
- Zacks
Jazz Pharma (JAZZ) Q2 Earnings and Sales Beat Estimates
Jazz Pharmaceuticals (JAZZ) reports encouraging second-quarter 2019 earnings and revenues and raises its sales guidance for 2019.
- Zacks
Corcept's (CORT) Earnings & Revenues Miss Estimates in Q2
Corcept (CORT) misses earnings and revenue estimates in the second quarter of 2019.
- Thomson Reuters StreetEvents
Edited Transcript of TBPH earnings conference call or presentation 31-Jul-19 12:00pm GMT
Q2 2019 Theravance Biopharma Inc Earnings Call
- Zacks
Theravance (TBPH) Q2 Loss Narrower, Revenues Beat Estimates
Theravance (TBPH) reports narrower-than-expected loss and beats on sales in the second quarter of 2019.
Motley FoolTheravance Biopharma, Inc. (TBPH) Q2 2019 Earnings Call Transcript
TBPH earnings call for the period ending June 30, 2019.
- Zacks
Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates
Theravance Bio (TBPH) delivered earnings and revenue surprises of 40.98% and 87.91%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Theravance Biopharma, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update
- Late-stage clinical studies of TD-1473 and ampreloxetine progressing - Phase 1 results including biomarker data in asthmatics for lung-selective inhaled pan-JAK inhibitor TD-8236 expected in September ...
- PR Newswire
Theravance Biopharma Reports New Data from Phase 2 Study of Ampreloxetine (TD-9855) in Oral Presentation at 32nd European Neurology Congress
DUBLIN, July 22, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today reported new data from the Company's Phase 2 clinical trial of ampreloxetine (TD-9855) in patients with neurogenic orthostatic hypotension (nOH) in an oral presentation at the 32nd European Neurology Congress. New data demonstrated that patients experienced improvements in their overall nOH symptoms and in their ability to perform daily activities following four weeks of treatment, and that these improvements were sustained until the completion of 20 weeks of ampreloxetine therapy.
- Simply Wall St.
How Much Did Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Pocket Last Year?
Rick Winningham has been the CEO of Theravance Biopharma, Inc. (NASDAQ:TBPH) since 2014. This report will, first...
- Zacks
AstraZeneca's Triple-Combo COPD Inhaler Gets Japan's Nod
AstraZeneca (AZN) gets approval in Japan for PT010, its triple-combo inhaler and Bevespi Aerosphere, a fixed-dose LABA/LAMA inhaler, both to treat COPD.
